Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOM230 for Reduction of Post-Pancreatectomy Complications
NCT00994110Phase 3Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2009
- Primary completion
- Sep 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic cancer (PC) comparing SOM230 with Placebo (2 arms). Primary endpoint: Rate of Grade 3 or Higher Pancreatic Fistula, Leak, and Abscess at 60 days. Started Oct 2009; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00994110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00994110.